Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Monotherapy in Stage I-II MSI-H/dMMR Endometrial Cancer
NCT07731607Phase 2Not yet recruiting
- Sponsor
- Wang Jianliu
- Start
- Jul 2026
- Primary completion
- Jul 2030
01
Overview
A Phase 2 trial of sintilimab in endometrial cancer (EC), sponsored by Wang Jianliu. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07731607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07731607.